Overview

A Study to Evaluate the Safety of the Coadministration of ANS-6637 and Ethanol

Status:
Completed
Trial end date:
2017-11-15
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, double-blind, placebo-controlled, single-ascending-dose study to evaluate the safety and tolerability of the coadministration of up to 6 dose levels of ANS-6637 and EtOH in healthy male moderate alcohol drinkers. The study will include a screening visit, a qualification visit, a Treatment Phase and follow-up.
Phase:
Phase 1
Details
Lead Sponsor:
Amygdala Neurosciences, Inc.
Treatments:
Ethanol